The Journal of Antibiotics · 2004 · 41 citations · 9 references
Life SciencesMicrobiologyMolecular BiologyDrug DesignDrug DiscoveryTranscriptionAntibacterial PharmacologyEnzyme InhibitionPolymerase Chain ReactionRna Polymerase FunctionRna Polymerase I TranscriptionRna TranscriptionAntibiotic DiscoveryAntibiotic Inhibition Of TranslationNovel Antibacterial Drug DiscoveryRna Polymerase I ActivityRna Polymerase I FunctionTranscription Inhibitors
GE 23077 factors A1, A2, B1 and B2 are novel antibiotics isolated from fermentation broths of an Actinomadura sp. strain. GE23077 antibiotics are cyclic peptides, which inhibit Escherichia coli RNA polymerase at nM concentrations. Both rifampicin-sensitive and rifampicin-resistant polymerases are inhibited, whereas E. coli DNA polymerase and wheat germ RNA polymerase are substantially not affected. In spite of the potent activity on the enzyme, the antibiotics generally show poor activity against whole cell bacteria. The spectrum of activity is restricted to Moraxella catarrhalis, including clinical isolates, with partial activity against Neisseria gonorrhoeae and Mycobacterium smegmatis.
9